Molecule Information

General Information of the Molecule (ID: Mol04005)

• Name: Chromosome 3 open reading frame 14 (C3orf14) ,Oncorhynchus mykiss
• Molecule Type: Protein
• Gene Name: C3orf14
• Sequence:
  MTSPPFEEVELNKKHEEILGKRAVLLQQMERRYEQQKNKRRQQVKLSQAAHERNSQLLQD
  LQKMENRLRTRVLPHPDILSLETRYWASVEEKIPEWERFLLGKGPHPSSDPSRTPKQQKL
  KTTPRDHAPTQDGALPPRPILKHVK
• Uniprot ID: A0A8C7TD83_ONCMY

Kingdom: Metazoa
Phylum: Chordata
Class: Actinopterygii
Order: Salmoniformes
Family: Salmonidae
Genus: Oncorhynchus
Species: Oncorhynchus mykiss

Type(s) of Resistant Mechanism of This Molecule

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Enzalutamide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Disease Class: Prostate cancer [ICD-11: 2C82.0] [1]

• Metabolic Type: Glutamine metabolism
• Resistant Disease: Prostate cancer [ICD-11: 2C82.0]
• Resistant Drug: Enzalutamide
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: C4-2B cells; Prostate; Homo sapiens (Human); CVCL_4784
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: We compared the transcriptomic profile of paired enzalutamide-sensitive and resistant LNCaP and C4-11B prostate cancer cells for identification of genes involved in drug resistance by performing an unbiased bioinformatics analysis and further validation

Disease Class: Prostate cancer [ICD-11: 2C82.0] [1]

• Metabolic Type: Glutamine metabolism
• Resistant Disease: Prostate cancer [ICD-11: 2C82.0]
• Resistant Drug: Enzalutamide
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: LNCaP cells; Prostate; Homo sapiens (Human); CVCL_0395
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: We compared the transcriptomic profile of paired enzalutamide-sensitive and resistant LNCaP and C4-2B prostate cancer cells for identification of genes involved in drug resistance by performing an unbiased bioinformatics analysis and further validation

References

• Ref 1: Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer. Cells. 2020 Nov 24;9(12):2535.